229 related articles for article (PubMed ID: 34294917)
1. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
[TBL] [Abstract][Full Text] [Related]
2. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
[TBL] [Abstract][Full Text] [Related]
3. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
bioRxiv; 2024 May; ():. PubMed ID: 38798502
[TBL] [Abstract][Full Text] [Related]
4. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
6. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
[TBL] [Abstract][Full Text] [Related]
7. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.
Jain SU; Khazaei S; Marchione DM; Lundgren SM; Wang X; Weinberg DN; Deshmukh S; Juretic N; Lu C; Allis CD; Garcia BA; Jabado N; Lewis PW
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27354-27364. PubMed ID: 33067396
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
9. Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.
Sanulli S; Justin N; Teissandier A; Ancelin K; Portoso M; Caron M; Michaud A; Lombard B; da Rocha ST; Offer J; Loew D; Servant N; Wassef M; Burlina F; Gamblin SJ; Heard E; Margueron R
Mol Cell; 2015 Mar; 57(5):769-783. PubMed ID: 25620564
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
Lavarone E; Barbieri CM; Pasini D
Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
[TBL] [Abstract][Full Text] [Related]
11. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
12. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
[TBL] [Abstract][Full Text] [Related]
13. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model.
Haag D; Mack N; Benites Goncalves da Silva P; Statz B; Clark J; Tanabe K; Sharma T; Jäger N; Jones DTW; Kawauchi D; Wernig M; Pfister SM
Cancer Cell; 2021 Mar; 39(3):407-422.e13. PubMed ID: 33545065
[TBL] [Abstract][Full Text] [Related]
14. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
17. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
18. Polycomb repressive complex 2 epigenomic signature defines age-associated hypermethylation and gene expression changes.
Dozmorov MG
Epigenetics; 2015; 10(6):484-95. PubMed ID: 25880792
[TBL] [Abstract][Full Text] [Related]
19. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
20. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
